Small Molecules Drug Design and Novel Inhibitors at the 15th Annual Advances and Progress in Drug Design Conference

Share Article

Returning for its 15th year and following on from the major success of previous events, SMi is proud to announce that the Advances and Progress in Drug Design conference will take place on 15th-16th February 2016 in London, UK.

News Image
This year’s new area of discussion include: Small molecules in drug design - A look at novel inhibitors and favourable protein-fragment interactions

This year’s event will focus on enabling biophysical tools and highlight key advancements in protein-based drug discovery, with new areas of discussion including: Small molecules in drug design - A look at novel inhibitors and favourable protein-fragment interactions. It will take a closer look at combined HTS and FBDD methods for lead generation and the application of biophysical methods such as: X-Ray Crystallography, NMR, Biocore and ITC to aid the prioritisation of target inhibitors.

Conference program will include interactive presentations, case studies and keynote addresses which will enable attendees to gain new insights in organised dynamic structures on a 3D project database using novel algorithms to determine specific subunits, as well as understand data mining workflows and the IMI Open PHACTS projects.

Plus, two interactive half-day post-conference workshops will be presented by Barcelona University: A fresh view on molecular recognition: the dynamic perspective; and C4X Discovery: Analysis and Application of Ligand Conformation in Drug Design.

Confirmed Sponsors for 2016: Chemical Computing Group and Openeye Scientific Software

Chair for 2016:

  • Gregg Seigal, Chief Executive Officer, ZoBio

Featured Speakers:

  • Doug Johnson, Research Fellow, Pfizer
  • Tove Sjögren, Associate Director, AstraZeneca
  • Herman van Vlijmen, Senior Director, Janssen
  • Paul Hawkins, Applications Science Group Leader, Open Eye Scientific Software
  • Armin Ruf, Section Head, Biostructure, Roche
  • Gianni Chessari, Director, Astex Pharmaceuticals
  • Hans Matter, Senior Scientist, Sanofi-Aventis, and many more

Those who are interested in attending are advised to register before 30th October to secure the place at the conference and save £400.

For the full event agenda/ to register please visit: http://www.drug-design.co.uk/prweb

-------------------------- END --------------------------
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Anna Serazetdinova
@Pareapp
Follow >
Anna Serazetdinova